Who are Tenax Therapeutics's investors?

Tenax Therapeutics's investors include Vivo Capital.

How much funding has Tenax Therapeutics raised?

Tenax Therapeutics has disclosed $123.2M raised across 5 of its 6 known rounds.

Where is Tenax Therapeutics headquartered?

Tenax Therapeutics is headquartered in Chapel Hill, US.

Tenax Therapeutics

NASDAQ: TENX

Chapel Hill, US · Delaware corporation · 1 known investors

Find your way into Tenax Therapeutics

Paths you didn't know you had: your email and LinkedIn already hold routes to the Tenax Therapeutics team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Tenax Therapeutics is a clinical-stage pharmaceutical company developing TNX-103, an oral formulation of the drug levosimendan, to treat pulmonary hypertension resulting from heart failure with preserved ejection fraction (PH-HFpEF). The company focuses on this cardiovascular and pulmonary disease, which currently has no approved treatments.

Biotech Digital Health Healthtech

Founders & leadership

Stuart RichChief Medical Officer

Lawrence R. Hoffman Interim Chief Financial OfficerLawrence R. Hoffman is a CPA and attorney with a Master of Laws in Taxation who brings extensive financial and legal experience in life sciences and contract research organizations. He has held senior financial roles at The Liposome Company, Averion International, and Sybron Chemicals, and has experience in M&A, IPOs, and SEC reporting.

Michael B. JebsenExecutive

Chris Giordano President and Chief Executive OfficerChris Giordano has spent more than two decades in clinical pharmaceutical development, holding leadership roles including President of Novella Clinical (later acquired into IQVIA) where he oversaw expansion of a clinical trial portfolio and integration of EU-based firms, and previously serving as Global Head of Cardiovascular, Renal and Metabolic Therapeutic Area at Quintiles, where he managed large-scale clinical trials in cardiology, immunology, and metabolic disease. He is now President and Chief Executive Officer of Tenax Therapeutics.

Doug RandallChief Business Officer

Tom StaabChief Financial Officer

Tim Healey Chief Commercial OfficerTim Healey is Chief Commercial Officer at Tenax Therapeutics and has held commercial leadership roles at EVERSANA, Lantheus, Abbott Laboratories/AbbVie, and AMAG Pharmaceuticals, with experience in product launches across primary care, specialty, and rare disease markets. He holds a B.S. from Boston College and an M.B.A. from Babson College.

Douglas HayEVP of Regulatory Affairs

So-Young Kim Executive Vice President of Clinical Development and StrategySo-Young Kim has over two decades of pharmaceutical industry experience spanning research, development, and commercialization, with specialist training in internal medicine and cardiology. She previously held senior leadership positions at Bayer AG overseeing strategic direction of a large pharmaceutical portfolio, and currently serves as Executive Vice President of Clinical Development and Strategy at Tenax Therapeutics.

Gregory PepinNamed on SEC filing

James MitchumNamed on SEC filing

Anthony DiTonnoChief Executive Officer2018–2021Executive Officer, Director at Avantis Medical Systems

Investors · 1

Vivo Capitallisted by Vivo CapitalPalo Alto · $10M – $50M

How we know: Vivo Capital's portfolio page · Not right? Tell us

Reported raises · per SEC filings

Form D private placements

$123.2M disclosed across 5 of 6 rounds · 1900–2024

▶$99.7MraisedAug 2024 · 24 investors · Pharmaceuticals

Rule 506(b)